enGene Therapeutics (ENGN) Non Operating Income (2023 - 2026)
enGene Therapeutics (ENGN) posted quarterly Non Operating Income of $1.7 million for Q2 2026, up 12.4% year-over-year from $1.5 million in Q2 2025, and up 21.49% quarter-over-quarter from $1.4 million in Q1 2026.
enGene Therapeutics (ENGN) Non Operating Income (2023 - 2026) Analysis & Trends
enGene Therapeutics (ENGN) has reported Non Operating Income for 4 consecutive years, with $1.7 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Non Operating Income rose 12.4% year-over-year to $1.7 million; the TTM figure through Apr 2026 stood at $5.5 million (down 34.23% YoY), while the FY2025 annual figure was $5.9 million, down 17.84% from the prior year.
- Non Operating Income rose to $1.7 million in Q2 2026 per ENGN's latest filing, from $1.4 million in the prior quarter.
- Across five years, Non Operating Income topped out at $2.6 million in Q3 2024 and bottomed at -$72.0 million in Q4 2023.
- Historically, Non Operating Income has averaged -$4.1 million across 4 years, with a median of $1.5 million in 2023.
- On a YoY basis, Non Operating Income climbed as much as 6196.88% in 2025 and fell as far as 53.72% in 2025.
- enGene Therapeutics' Non Operating Income stood at -$72.0 million in 2023, then soared by 103.02% to $2.2 million in 2024, then tumbled by 49.24% to $1.1 million in 2025, then jumped by 57.7% to $1.7 million in 2026.
- Business Quant data shows ENGN's Non Operating Income at $1.7 million in Q2 2026, $1.4 million in Q1 2026, and $1.1 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -53.64 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -51.63 Mn |
| 10 | enGene Therapeutics | 124.11 Mn | 124.11 Mn | - | 1.74 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 1.74 Mn |
| Jan 31, 2026 | 1.43 Mn |
| Oct 31, 2025 | 1.10 Mn |
| Jul 31, 2025 | 1.20 Mn |
| Apr 30, 2025 | 1.55 Mn |
| Jan 31, 2025 | 2.02 Mn |
| Oct 31, 2024 | 2.18 Mn |
| Jul 31, 2024 | 2.58 Mn |
| Apr 30, 2024 | 2.35 Mn |
| Jan 31, 2024 | 32,000.00 |
| Oct 31, 2023 | -72.04 Mn |
| Jul 31, 2023 | 1.53 Mn |
| Apr 30, 2023 | -545,000.00 |
| Jan 31, 2023 | -2.79 Mn |